Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasmodium falciparum | 18 | 2013 | 146 | 1.830 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.910 |
Why?
|
| Biomedical Research | 3 | 2025 | 467 | 0.870 |
Why?
|
| Malaria, Falciparum | 6 | 2013 | 91 | 0.810 |
Why?
|
| Merozoite Surface Protein 1 | 8 | 2010 | 34 | 0.800 |
Why?
|
| Cooperative Behavior | 1 | 2025 | 250 | 0.800 |
Why?
|
| Education, Medical | 1 | 2024 | 117 | 0.790 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2022 | 4 | 0.780 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 11 | 0.770 |
Why?
|
| Curriculum | 1 | 2024 | 311 | 0.720 |
Why?
|
| Antigens, Protozoan | 12 | 2002 | 74 | 0.690 |
Why?
|
| Antibodies, Protozoan | 12 | 2010 | 82 | 0.630 |
Why?
|
| Health Services, Indigenous | 1 | 2018 | 33 | 0.540 |
Why?
|
| Schools, Medical | 1 | 2018 | 208 | 0.480 |
Why?
|
| Metabolome | 1 | 2013 | 50 | 0.390 |
Why?
|
| Metabolomics | 1 | 2013 | 90 | 0.380 |
Why?
|
| Protozoan Proteins | 5 | 1994 | 196 | 0.380 |
Why?
|
| Erythrocytes | 1 | 2013 | 126 | 0.380 |
Why?
|
| Epitopes | 4 | 2010 | 155 | 0.360 |
Why?
|
| Protein Precursors | 3 | 1994 | 59 | 0.320 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 87 | 0.310 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 253 | 0.290 |
Why?
|
| Research Personnel | 3 | 2025 | 191 | 0.280 |
Why?
|
| Malaria Vaccines | 3 | 2010 | 21 | 0.260 |
Why?
|
| Humans | 15 | 2025 | 42163 | 0.240 |
Why?
|
| Leptospira | 1 | 2025 | 27 | 0.230 |
Why?
|
| Leptospirosis | 1 | 2025 | 30 | 0.230 |
Why?
|
| Lymphocyte Activation | 2 | 2022 | 244 | 0.220 |
Why?
|
| Minority Groups | 2 | 2021 | 663 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 3 | 1994 | 117 | 0.210 |
Why?
|
| Antigens, Surface | 5 | 1994 | 50 | 0.210 |
Why?
|
| Genetic Variation | 1 | 2005 | 429 | 0.200 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 9 | 0.200 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2022 | 11 | 0.190 |
Why?
|
| Interleukin-4 | 1 | 2022 | 75 | 0.190 |
Why?
|
| Cytokines | 2 | 2022 | 661 | 0.180 |
Why?
|
| Ligands | 1 | 2022 | 387 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 1993 | 301 | 0.170 |
Why?
|
| Cross Reactions | 4 | 2010 | 86 | 0.160 |
Why?
|
| Hawaii | 3 | 2025 | 2004 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2022 | 633 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 86 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 96 | 0.140 |
Why?
|
| Colombia | 2 | 2010 | 30 | 0.140 |
Why?
|
| Baculoviridae | 3 | 2002 | 14 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 522 | 0.130 |
Why?
|
| United States | 2 | 2025 | 5072 | 0.130 |
Why?
|
| Animals | 17 | 2025 | 16695 | 0.120 |
Why?
|
| Alleles | 3 | 2010 | 352 | 0.120 |
Why?
|
| Genotype | 2 | 2010 | 796 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 1994 | 27 | 0.110 |
Why?
|
| Cyclic ADP-Ribose | 1 | 2013 | 3 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2013 | 98 | 0.100 |
Why?
|
| Glycolysis | 1 | 2013 | 71 | 0.100 |
Why?
|
| Arginine | 1 | 2013 | 75 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 71 | 0.100 |
Why?
|
| Rabbits | 5 | 2008 | 292 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 279 | 0.090 |
Why?
|
| Antibody Specificity | 5 | 2008 | 76 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 336 | 0.090 |
Why?
|
| Seeds | 1 | 2010 | 46 | 0.080 |
Why?
|
| Papua New Guinea | 1 | 2010 | 21 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 973 | 0.080 |
Why?
|
| Cameroon | 1 | 2010 | 35 | 0.080 |
Why?
|
| Child | 2 | 2010 | 3381 | 0.080 |
Why?
|
| Arabidopsis | 1 | 2010 | 102 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 203 | 0.080 |
Why?
|
| Protozoan Vaccines | 3 | 1994 | 16 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 1066 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2535 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2008 | 456 | 0.070 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 78 | 0.070 |
Why?
|
| Amino Acid Sequence | 6 | 2008 | 1188 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2022 | 1729 | 0.070 |
Why?
|
| Adolescent | 2 | 2010 | 5950 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 1143 | 0.060 |
Why?
|
| Mice | 7 | 1996 | 6490 | 0.060 |
Why?
|
| Zoonoses | 1 | 2025 | 20 | 0.060 |
Why?
|
| DNA | 1 | 1988 | 594 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 1516 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2002 | 1559 | 0.050 |
Why?
|
| Male | 3 | 2025 | 22779 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2002 | 5 | 0.050 |
Why?
|
| Granulocytes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immune Sera | 3 | 1992 | 56 | 0.050 |
Why?
|
| Female | 3 | 2025 | 24018 | 0.050 |
Why?
|
| Middle Aged | 2 | 2010 | 11819 | 0.050 |
Why?
|
| Incidence | 1 | 2025 | 1054 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1994 | 116 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 166 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 162 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 1996 | 301 | 0.050 |
Why?
|
| Adult | 2 | 2010 | 13458 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 61 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 24 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 378 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 774 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 118 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 4936 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 1992 | 1804 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Base Sequence | 2 | 1992 | 997 | 0.040 |
Why?
|
| Species Specificity | 2 | 1989 | 279 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 187 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 729 | 0.030 |
Why?
|
| Aged | 1 | 2010 | 7982 | 0.030 |
Why?
|
| Immunization | 2 | 1992 | 93 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 45 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3077 | 0.030 |
Why?
|
| Immunoblotting | 2 | 1996 | 181 | 0.030 |
Why?
|
| Primates | 1 | 1994 | 38 | 0.030 |
Why?
|
| Haplotypes | 1 | 1994 | 197 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 183 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 705 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 25 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 21 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 90 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1992 | 107 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1992 | 96 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 196 | 0.020 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Lipid A | 1 | 1991 | 8 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 1991 | 14 | 0.020 |
Why?
|
| Hybridomas | 2 | 2002 | 24 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 884 | 0.020 |
Why?
|
| Vaccination | 1 | 1992 | 332 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1989 | 75 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 198 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1988 | 45 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 34 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1988 | 54 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 100 | 0.020 |
Why?
|
| Vaccines | 1 | 1988 | 64 | 0.020 |
Why?
|
| Malaria | 1 | 1988 | 90 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1988 | 200 | 0.020 |
Why?
|
| Water | 1 | 1988 | 314 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Single-Chain Antibodies | 1 | 2002 | 3 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2002 | 22 | 0.010 |
Why?
|
| Spodoptera | 1 | 2002 | 17 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2002 | 59 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2002 | 83 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 99 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 268 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 526 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 379 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 1416 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 39 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1991 | 21 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 221 | 0.010 |
Why?
|
| Peptides | 1 | 1991 | 357 | 0.000 |
Why?
|